stockrowKiniksa Pharmaceuticals International, plc
KNSA Healthcare Drug Manufacturers Specialty & Generic
Kiniksa Pharmaceuticals International, plc’s revenue for fiscal 2025 (year ended December 2025) was $677.6 million, up 60.1% from fiscal 2024.
- Revenue
- +58.1%
- EPS
- +142.2%
- Free cash flow
- +43.5%
Quarter to September 2026, against a year earlier
Follow KNSA
Alert me
Kiniksa Pharmaceuticals International, plc (KNSA) EBITDA
Kiniksa Pharmaceuticals International, plc's EBITDA for fiscal 2025 was $78.8M, compared with −$43.9M in fiscal 2024. Over the twelve months to 30 September 2026 it was $132.4M. Over the past ten years it has ranged from −$167.9M (fiscal 2019) to $78.8M (fiscal 2025) — the current reading is the highest in ten years. Kiniksa Pharmaceuticals International, plc ranks 21st of 80 Drug Manufacturers Specialty & Generic companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | $78.8M | — |
| FY2024 | −$43.9M | — |
| FY2023 | −$22.9M | — |
| FY2022 | $12.2M | — |
| FY2021 | −$154.3M | — |
| FY2020 | −$155.0M | — |
| FY2019 | −$167.9M | — |
| FY2018 | −$107.9M | — |
| FY2017 | −$65.4M | — |
| FY2016 | −$24.0M | — |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Sep 2026 | $54.7M | 97.81% |
| Jun 2026 | $27.7M | (6.96%) |
| Mar 2026 | $29.7M | 46.95% |
| Dec 2025 | $20.2M | (17.09%) |
| 33 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| ELAN Elanco Animal Health Incorporated compare | $774.0M |
| AMRX AMNEAL PHARMACEUTICALS, INC. compare | $664.9M |
| SUPN Indivior Pharmaceuticals Inc. compare | $571.0M |
| RDY Dr. Reddy's Laboratories Ltd compare | $526.8M |
| LNTH Lantheus Holdings, Inc. compare | $386.4M |
| ALKS Alkermes plc compare | $217.3M |
| LQDA Liquidia Corporation compare | $170.3M |
| KNSA Kiniksa Pharmaceuticals International, plc | $132.4M |
| HIMS Hims & Hers Health, Inc. compare | −$62.2M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on KNSA
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement